NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

hyperopia, Thank you for your thoughtful post. You've pulled together several ideas that sound like a solid plan for NWBO moving forward. I really appreciate you noting Daiichi Sankyo's CSF1R inhibitor in your post. I can never hold onto new names and molecules in my head, but I knew there was a proposed 4th ingredient in the proposed next trial. I'm glad to hear you believe they've in-licensed it. I guess we'll soon find out.
I'm still curious about Dr. Liau's comment that poly iclc is part of DCVax-L and, if it's true, I don't know how an RA deals with that combo if DCVax-L without poly iclc becomes the new standard of care. Any thoughts?
Also, I hope you address dstock's question on the idea that the company and MHRA have lots of data from the specials program on how effective poly iclc works. It's real world data, but that's what we appear to be using now as comparatives instead of placebos. I think he's got a point.